In an interview with Targeted Oncology, Natalie Berger, MD, hematologist and oncologist at the New York Presbyterian Medical Group, weighed the biggest hurdles she witnesses in HPV vaccination and ...

Enrollment has been completed for a phase 2a randomized clinical trial evaluating the investigational microbiome therapeutic EBX-102-02 in patients undergoing allogeneic hematopoietic stem cell ...

In this interview, Sagar Lonial, MD, discussed the EXCALIBER-RRMM trial design and the potential role of iberdomide in the ...

Interim phase 1b data showed 100% partial response rate in efficacy-evaluable CLL/SLL (4/4) after a median of at least three prior treatment lines. In heavily pretreated MZL (n=5), three complete ...

ctDNA MRD monitoring offers new clues for stopping chemo safely in metastatic gastroesophageal cancer, linking molecular response to outcomes. In an interview with Targeted Oncology, Rutika Mehta, MD, ...

Lifileucel (Amtagvi) is an approved tumor-infiltrating lymphocyte (TIL) therapy for patients with advanced melanoma, but there are limited data on treatment of patients with brain ...

A novel immunotherapy combination is proving to be both safe and manageable for patients with prostate cancer, according to updated Phase 1 trial data presented at the 2026 ASCO Genitourinary Cancers ...

Posttransplant cyclophosphamide–containing prophylaxis correlated with lower aGVHD risk than tacrolimus/methotrexate, and ATG/alemtuzumab use contributed to risk estimation. Clinical utility includes ...

ctDNA MRD monitoring may augment scans and tumor markers, enabling earlier detection of gastroesophageal cancer recurrence, especially hard-to-image peritoneal relapse.

New trial data suggest azacitidine-venetoclax may rival 7+3 in AML, shifting induction toward targeted, less toxic combinations.

PI3K/AKT/mTOR pathway blockade with pan-PI3K/mTORC1/2 inhibition produced substantial PFS gains in PIK3CA wild-type disease, addressing an unmet need after CDK4/6 plus endocrine resistance. Adding ...

Co-occurring alterations in EGFR-mutant NSCLC are increasingly detected via broad NGS and may signal aggressive biology, prompting interest in escalation strategies that address concurrent drivers.